Data Provided by Refinitiv. Minimum 15 minutes delayed.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Nov 30, 2021 at 1:00 PM EST
Nov 16, 2021 at 7:20 AM EST
Nov 9, 2021 at 4:30 PM EST
Nov 10, 2021
Nov 09, 2021
Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor RelationsNov 08, 2021